Updated prevalence of genotypic resistance among HIV‐1 positive patients naïve to antiretroviral therapy: a single center analysis

Continuous surveillance of HIV primary resistance mutations is highly important due to their potential clinical impact. All patients naïve to antiretrovirals who had ≥1 genotypic resistance testing at the Institute of Infectious Diseases (Brescia, Northern Italy) between 2001 and 2006 were analyzed. Primary resistance mutations were defined using epidemiological and clinical criteria. Mutations were interpreted using the Stanford University Algorithm. Logistic regression analysis was used to assess possible predictors of primary resistance mutations. Among 569 patients, 11% presented ≥1 mutation. Prevalence of primary resistance mutations to nucleoside reverse‐transcriptase inhibitors (NRTI), non‐nucleoside reverse‐transcriptase inhibitors (NNRTI), and protease inhibitors (PI) was 6.3%, 6%, and 1.6%, respectively. The most frequent mutations to NRTI were substitutions at position 215 (215Y in 3 patients, and 215 revertants in 16), 41L (13), 219Q (12), and 210W (10). Among mutations to NNRTI, 103N was found in 21 patients, while 181C, 188L, and 190A/S in 8, 3, and 4 patients, respectively. Fifty‐one patients (9%) had high‐to‐intermediate resistance to ≥1 antiretroviral drug before starting the treatment. Regarding the new generation drugs, nine patients had intermediate resistance to etravirine, five patients had intermediate resistance to tipranavir, while five, one, and seven patients had low resistance to etravirine, tipranavir, and darunavir. Homosexuals were more likely to harbor a virus with primary resistance mutations (OR:2.68; 95% CI:1.44–5.00; P = 0.002) while non‐Italian nationality was protective (OR:0.38; 95% CI:0.17–0.86; P = 0.020). Prevalence of primary resistance mutations suggests that genotypic resistance testing should be performed before starting treatment in naïve patients in Italy, particularly when NNRTI are prescribed. J. Med. Virol. 80:747–753, 2008. © 2008 Wiley‐Liss, Inc.

[1]  A. Geretti.  Epidemiology of antiretroviral drug resistance in drug-naïve persons , 2007, Current opinion in infectious diseases.

[2]  R. Kaiser,et al.  Primary HIV Drug Resistance and Efficacy of First-Line Antiretroviral Therapy Guided by Resistance Testing , 2006, Journal of acquired immune deficiency syndromes.

[3]  C. Torti,et al.  Prevalence of drug resistance and newly recognised treatment-related substitutions in the HIV-1 reverse transcriptase and protease genes from HIV-positive patients naïve for anti-retrovirals. , 2004, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[4]  M. Chesney,et al.  Antiretroviral drug resistance, HIV-1 tropism, and HIV-1 subtype among men who have sex with men with recent HIV-1 infection , 2007, AIDS.

[5]  Elizabeth Connick,et al.  Antiretroviral-drug resistance among patients recently infected with HIV. , 2002, The New England journal of medicine.

[6]  Klaus Korn,et al.  Prevalence of drug-resistant HIV-1 variants in untreated individuals in Europe: implications for clinical management. , 2005, The Journal of infectious diseases.

[7]  Soo-Yon Rhee,et al.  HIV-1 protease and reverse transcriptase mutations for drug resistance surveillance , 2007, AIDS.

[8]  Simon D W Frost,et al.  Long-term persistence of transmitted HIV drug resistance in male genital tract secretions: implications for secondary transmission. , 2007, The Journal of infectious diseases.

[9]  L. Bacheler,et al.  Rare mutations at codon 103 of HIV-1 reverse transcriptase can confer resistance to non-nucleoside reverse transcriptase inhibitors , 2005, AIDS.

[10]  Alessandro Cozzi-Lepri,et al.  Risk of failure in patients with 215 HIV-1 revertants starting their first thymidine analog-containing highly active antiretroviral therapy , 2004, AIDS.

[11]  S. Little.  Transmission and Prevalence of HIV Resistance among Treatment-Naive Subjects , 2000, Antiviral therapy.

[12]  A. Phillips,et al.  Prevalence and predictors of antiretroviral drug resistance in newly diagnosed HIV-1 infection. , 2007, The Journal of antimicrobial chemotherapy.

[13]  D. Pillay,et al.  Time trends in primary resistance to HIV drugs in the United Kingdom: multicentre observational study , 2005, BMJ : British Medical Journal.

[14]  R. Kaiser,et al.  Trends of prevalence of primary HIV drug resistance in Germany. , 2007, The Journal of antimicrobial chemotherapy.

[15]  A. Kamarulzaman,et al.  Short communication: low prevalence of genotypic drug resistance mutations among antiretroviral-naive HIV type 1 patients in Malaysia. , 2006, AIDS research and human retroviruses.

[16]  Jonathan M. Schapiro,et al.  Genotypic Changes in Human Immunodeficiency Virus Type 1 Protease Associated with Reduced Susceptibility and Virologic Response to the Protease Inhibitor Tipranavir , 2006, Journal of Virology.

[17]  H. Sørensen,et al.  Declining Prevalence of HIV-Infected Individuals at Risk of Transmitting Drug-Resistant HIV in Denmark during 1997–2004 , 2005, Antiviral therapy.

[18]  S. Spector,et al.  Prevalence of primary HIV-1 drug resistance among recently infected adolescents: a multicenter adolescent medicine trials network for HIV/AIDS interventions study. , 2006, The Journal of infectious diseases.

[19]  M. Mouroux,et al.  Resistance profile and cross‐resistance of HIV‐1 among patients failing a non‐nucleoside reverse transcriptase inhibitor‐containing regimen * , 2001, Journal of medical virology.

[20]  F. Bastos,et al.  Trends in drug resistance mutations in antiretroviral‐naïve intravenous drug users of Rio de Janeiro , 2006, Journal of medical virology.

[21]  D. Pillay,et al.  Evolution of Transmitted HIV-1 with Drug-Resistance Mutations in the Absence of Therapy: Effects on Cd4+ T-Cell Count and HIV-1 Rna Load , 2006, Antiviral therapy.

[22]  John P. Walsh,et al.  Evidence of a decline in transmitted HIV-1 drug resistance in the United Kingdom , 2007, AIDS.

[23]  A. Monforte,et al.  Prevalence of HIV-1 primary drug resistance in seroconverters of the ICoNA cohort over the period 1996-2001. , 2004, Journal of acquired immune deficiency syndromes.

[24]  JD Lundgren,et al.  Updated European Recommendations for the Clinical Use of HIV Drug Resistance Testing , 2004, Antiviral therapy.

[25]  M. Peeters,et al.  HIV-1 Drug-Resistance Mutations among Newly Diagnosed Patients before Scaling-Up Programmes in Burkina Faso and Cameroon , 2005, Antiviral therapy.

[26]  Jonathan AC Sterne,et al.  Long-term effectiveness of potent antiretroviral therapy in preventing AIDS and death: a prospective cohort study , 2005, The Lancet.